PT Suparma Tbk (SPMA) Stock Analysis 2026: Is This Indonesian Paper Stock Worth Buying?
 |
| PT Suparma Tbk (SPMA) |
Worldreview1989 - PT Suparma Tbk (IDX: SPMA) is a small-cap Indonesian paper manufacturer that may look unusual to U.S. investors. It is not a U.S.-listed company, its shares trade in Indonesian rupiah, and its business is exposed to paper prices, energy costs, foreign-exchange movements, and domestic Indonesian demand.
For American readers, however, SPMA offers an interesting case study: a profitable manufacturing company trading at a very low price-to-book multiple, but with relatively modest returns on equity and significant dependence on manufacturing economics.
The latest company financial statements available on Suparma's investor-relations website include the June 2026 financial statement, while the company's audited 2025 statements are also listed there.
Bottom line: SPMA looks inexpensive on book value and reasonably valued on earnings, but the investment case depends heavily on whether the company can improve margins and generate a higher return on its substantial asset base. For a U.S. investor, I would classify SPMA as a high-risk value/cyclical stock rather than a conventional dividend-growth investment.
What Is PT Suparma Tbk?
PT Suparma Tbk was established in 1976 and is headquartered in Surabaya, Indonesia. The company manufactures paper and related products, including industrial paper, tissue, towel paper and packaging-related products.
The company's product portfolio can broadly be divided into two categories:
Industrial products
Duplex board
Ribbed kraft
Samson kraft
Base paper
Machine-glazed paper
Consumer products
Tissue
Towel paper
Laminated wrapping kraft
Laminated machine-glazed paper
The company says it uses recovered fibers for many of its products and has FSC and ISO 14000 certifications.
For American investors, the important point is that SPMA is not simply a tissue company. It is a broader paper and packaging manufacturer whose economics are influenced by industrial demand as well as consumer products.
SPMA Stock Price in 2026
As of August 18, 2026, SPMA was quoted around Rp164 per share.
Reuters reported SPMA at around Rp165 in August 2026, while historical market data also shows the stock trading around the mid-Rp160s during August.
At approximately Rp164, the company's market capitalization is roughly Rp670–875 billion depending on the share count and market-data convention, making SPMA a relatively small company compared with major Indonesian paper producers.
That small size is important.
A U.S. investor should not evaluate SPMA like Apple, Microsoft or even a large emerging-market industrial company. Liquidity, institutional coverage and price volatility can be considerably different for a small Indonesian stock.
2025 Financial Performance
SPMA's 2025 results were relatively stable rather than spectacular.
| Metric | FY2024 | FY2025 | Change |
|---|---|---|---|
| Revenue | Rp2.730T | Rp2.741T | +0.4% |
| Gross Profit | Rp412.8B | Rp434.4B | +5.2% |
| EBITDA | Rp203.8B | Rp212.4B | +4.2% |
| Net Income | Rp104.8B | Rp106.2B | +1.3% |
| Net Margin | ~3.8% | ~3.9% | Slightly higher |
| EPS | ~Rp25.57 | ~Rp25.91 | +1.3% |
The 2025 figures show a business that maintained profitability despite essentially flat revenue.
The positive interpretation
Revenue barely increased, but gross profit increased faster than revenue.
That suggests some improvement in gross economics.
Gross profit increased approximately:
Rp434.4B − Rp412.8B = Rp21.6B
while revenue increased only about:
Rp11.1B
This is a modest but encouraging sign.
The negative interpretation
The improvement did not translate into a dramatic increase in net income.
Net profit rose only about 1.3%.
This tells investors something important:
SPMA's biggest opportunity may not be revenue growth—it may be margin expansion.
If the company can increase profitability without requiring proportionally more capital, shareholder returns could improve significantly.
The Biggest Concern: 2026 Profitability
The latest six-month 2026 figures make the investment case more complicated.
For the first half of 2026, SPMA reported:
| Metric | 6M 2025 | 6M 2026 | YoY |
|---|---|---|---|
| Revenue | Rp1.288T | Rp1.363T | +5.8% |
| Gross Profit | Rp202.5B | Rp242.7B | +19.9% |
| EBITDA | Rp85.3B | Rp123.6B | +44.9% |
| Net Income | Rp53.1B | Rp36.9B | -30.5% |
| Gross Margin | 15.7% | 17.8% | Improved |
| EBITDA Margin | 6.6% | 9.1% | Improved |
| Net Margin | 4.1% | 2.7% | Declined |
These figures come from the company's latest June 2026 financial statement availability and financial-data reporting on the first-half results.
This creates a very interesting situation.
Revenue: positive
Revenue increased 5.8%.
Gross profit: very positive
Gross profit increased almost 20%.
EBITDA: excellent
EBITDA increased almost 45%.
Net income: negative
Net income fell approximately 30.5%.
That divergence deserves close attention.
Why Is Net Profit Falling While EBITDA Is Rising?
This is one of the most important questions for SPMA investors.
The first-half 2026 numbers suggest that the company's underlying operating economics improved, but those improvements were not fully reaching the bottom line.
Possible explanations include:
higher depreciation;
financing costs;
foreign-exchange movements;
tax expenses;
other non-operating expenses;
changes in working capital;
investment-related costs.
The reported first-half interest expense was approximately Rp25.3 billion.
For investors, this means EBITDA alone should not be used to declare SPMA a turnaround story.
Cash flow and net income matter.
Balance Sheet Analysis
At June 2026, SPMA reported approximately:
Cash: Rp127.1 billion
Total assets: Rp3.907 trillion
Short-term debt: Rp592.5 billion
Long-term debt: Rp241.4 billion
Total equity: Rp2.526 trillion
The reported debt-to-equity ratio was approximately 0.33x.
This is actually one of the more attractive parts of the story.
Net debt
Approximate interest-bearing debt:
Rp592.5B + Rp241.4B = Rp833.9B
Less cash:
Rp833.9B − Rp127.1B = Rp706.8B
So estimated net debt is approximately:
Rp707 billion
That is meaningful relative to the company's equity.
However, the debt-to-equity ratio of roughly 0.33x is not excessively high for a manufacturing business.
Is SPMA Financially Safe?
I would describe the balance sheet as manageable but not risk-free.
The company's EBITDA for 6M 2026 was approximately Rp123.6 billion, while interest expense was about Rp25.3 billion.
That produces an approximate:
EBITDA / Interest Expense = 4.9x
The reported figure is also approximately 4.9x.
For an industrial company, this is not alarming.
But it is also not so strong that investors can ignore interest-rate and refinancing risks.
A U.S. investor should therefore monitor:
Net debt
Interest expense
Operating cash flow
Capital expenditure
Debt maturities
Working-capital requirements
SPMA Valuation at Around Rp164
This is where SPMA becomes interesting.
The company reported FY2025 EPS of approximately Rp25.91.
At a share price of Rp164:
P/E = Rp164 / Rp25.91 ≈ 6.3x
That is inexpensive compared with many developed-market industrial stocks.
However, investors should be careful.
The 2025 earnings may not represent normalized future earnings because 2026 earnings are currently weaker at the net-income level.
What If We Annualize 2026 Earnings?
6M 2026 EPS was approximately Rp9.00.
A simplistic annualization would be:
Rp9 × 2 = Rp18 EPS
At Rp164:
Forward-style P/E ≈ 164 / 18 = 9.1x
This is still relatively inexpensive.
But this is not a formal analyst forecast.
It assumes the second half of 2026 performs similarly to the first half.
Investors should therefore treat Rp18 as a scenario rather than a target.
Price-to-Book Value Is Particularly Interesting
At June 2026, reported book value per share was approximately Rp616.14, while SPMA traded around Rp167 at the time of the financial analysis.
At Rp164:
P/B ≈ 164 / 616 = 0.27x
That means investors are paying only about 27% of reported book value.
This is an extremely low valuation.
But there is a critical caveat:
A stock trading below book value is not automatically undervalued.
The real question is whether the company can generate attractive returns on that book value.
The ROE Problem
SPMA's reported ROE for the first half of 2026 was only approximately 1.46%.
That is weak.
This creates the central contradiction in the SPMA investment thesis:
Low P/B + low ROE
A company can remain below book value for years if its assets produce inadequate returns.
For SPMA to achieve a significant valuation rerating, investors would ideally want to see:
higher net margins;
higher ROE;
stronger free cash flow;
declining leverage;
more consistent earnings.
What American Investors May Like About SPMA
From a U.S. investor perspective, there are several attractive characteristics.
1. Extremely low P/B
A P/B ratio around 0.27x gives the stock a substantial valuation cushion on paper.
2. Positive EBITDA
SPMA remains an operatingly profitable manufacturing company.
3. Revenue growth in 2026
First-half revenue increased 5.8%.
4. Improving gross margin
Gross margin increased to approximately 17.8% in 6M 2026.
5. Improving EBITDA
EBITDA grew approximately 45% year over year in the first half.
These are meaningful operational improvements even though net income declined.
What American Investors May Dislike
The concerns are equally important.
1. Very low net margin
FY2025 net margin was approximately 3.9%.
That leaves relatively little room for unexpected cost increases.
2. Weak ROE
A low ROE means the company is not currently generating impressive returns on shareholder capital.
3. Cyclical paper industry
Paper manufacturers can be exposed to:
pulp prices;
recycled-fiber costs;
electricity;
fuel;
transportation;
packaging demand;
currency movements.
4. Small-cap liquidity
SPMA is substantially smaller and less liquid than large global paper companies.
A U.S. investor cannot assume the same execution quality or trading liquidity as a large NYSE/Nasdaq company.
5. Currency risk
A U.S. investor ultimately evaluates returns in U.S. dollars.
Suppose SPMA rises:
20% in IDR
but the Indonesian rupiah falls:
10% against the USD.
The approximate USD return would be:
1.20 × 0.90 − 1 = +8%
So the U.S. investor would receive roughly 8%, not 20%.
What About Dividends?
SPMA should not currently be viewed primarily as a dividend-growth stock.
The company has also undertaken a stock-dividend distribution, with market sources reporting a 30-for-100 stock-dividend distribution in July 2026.
A stock dividend is different from a cash dividend.
It increases the number of shares owned but does not by itself create economic value in the way a cash dividend does.
For investors, this means historical EPS and per-share metrics should be interpreted carefully around the share-count change.
How American Value Investors Might Analyze SPMA
A U.S. value investor could divide the thesis into three scenarios.
Bear Case
The company experiences:
weak paper demand;
higher raw-material costs;
persistent financing costs;
low net margins;
weak ROE.
In this scenario, SPMA could remain a value trap despite trading below book value.
Base Case
Revenue grows modestly, gross margins remain healthy, EBITDA improves, and net income gradually recovers.
Under this scenario, the stock's low P/E and P/B ratios could provide reasonable upside.
Bull Case
SPMA achieves:
stronger paper pricing;
higher production utilization;
better product mix;
sustained EBITDA growth;
lower financing costs;
stronger net income.
If ROE improves materially, the market could potentially assign a higher valuation multiple.
Simple Scenario Valuation
Using FY2025 EPS of approximately Rp25.91:
| P/E Multiple | Implied Price |
|---|---|
| 5x | Rp130 |
| 7x | Rp181 |
| 9x | Rp233 |
| 11x | Rp285 |
| 13x | Rp337 |
These are illustrative valuation scenarios, not price targets.
At Rp164, a 7x multiple would imply approximately Rp181.
A 9x multiple would imply approximately Rp233.
An 11x multiple would imply approximately Rp285.
But the stock would need sustainable earnings to justify those multiples.
What Would Make SPMA a Better Investment?
I would watch five indicators over the next 4–6 quarters.
1. Net income growth
The first priority is to determine whether the 2026 net-income decline is temporary.
2. ROE
ROE should ideally move substantially above its current low level.
3. EBITDA-to-interest coverage
The current roughly 4.9x level is acceptable, but stronger coverage would reduce financial risk.
4. Free cash flow
A profitable paper company still needs significant capital to maintain machinery and production facilities.
5. Debt reduction
If SPMA can reduce net debt while simultaneously growing EBITDA, the equity story becomes substantially stronger.
SPMA vs. a Typical U.S. Paper Stock
An American investor might instinctively compare SPMA with companies such as International Paper, Packaging Corporation of America or WestRock/Smurfit WestRock.
But this comparison needs caution.
SPMA is:
much smaller;
Indonesian;
exposed to different labor and energy economics;
exposed to IDR/USD currency risk;
less liquid;
less covered by global institutional analysts.
Therefore, SPMA's low valuation should not automatically be interpreted as a discount that must disappear.
Some of that discount may be a small-cap and emerging-market risk premium.
Is SPMA Stock a Buy in 2026?
My fundamental assessment would be:
SPMA = SPECULATIVE VALUE / WATCHLIST
Not a clear-cut buy.
The valuation is attractive:
P/E based on FY2025 earnings: roughly 6.3x at Rp164.
P/B: roughly 0.27x.
Debt/equity: roughly 0.33x.
FY2025 net income: Rp106.2 billion.
6M 2026 revenue growth: +5.8%.
6M 2026 EBITDA growth: +44.9%.
But the main weakness is profitability quality:
6M 2026 net income fell 30.5%.
ROE remains low.
Net margin is only about 2.7%.
The business remains capital intensive.
The stock has meaningful emerging-market and liquidity risks.
My Investment Scorecard
| Category | Assessment |
|---|---|
| Valuation | ⭐⭐⭐⭐⭐ |
| Revenue Growth | ⭐⭐⭐ |
| EBITDA Growth | ⭐⭐⭐⭐ |
| Net Profit Growth | ⭐⭐ |
| ROE | ⭐⭐ |
| Balance Sheet | ⭐⭐⭐ |
| Dividend Appeal | ⭐⭐ |
| Business Stability | ⭐⭐⭐ |
| Liquidity | ⭐⭐ |
| Long-Term Upside | ⭐⭐⭐⭐ |
| Overall | 3.4/5 |
The most attractive feature is clearly valuation.
The biggest concern is low returns on capital despite a substantial asset base.
Final Verdict for U.S. Investors
PT Suparma Tbk is an interesting example of a deep-value emerging-market manufacturing stock.
At around Rp164, investors are paying far less than the company's reported book value and a relatively low multiple of its 2025 earnings. The first half of 2026 also shows encouraging improvement in revenue, gross profit and EBITDA.
However, the falling net income tells us that operational improvement has not yet translated into stronger shareholder profitability.
That distinction is critical.
Cheap is not the same as undervalued.
For SPMA to become a compelling long-term investment, I would want to see three things:
Net income return to sustainable growth.
ROE move materially higher.
Debt and financing costs become less burdensome.
If those conditions occur while the stock remains below or near book value, the valuation could become much more compelling.
For now, I would categorize SPMA as:
A high-risk, potentially undervalued Indonesian paper stock that deserves a place on a value investor's watchlist—but requires confirmation through improving ROE, net income and cash flow before becoming a high-conviction investment.
Important Note for American Readers
SPMA trades on the Indonesia Stock Exchange (IDX) rather than the NYSE or Nasdaq. U.S. investors considering Indonesian equities should account for brokerage access, currency conversion, foreign-investment rules, liquidity, taxation and country risk.
This article is educational and is not personalized investment advice.
Primary & Credible References
PT Suparma Tbk — Official Financial Statements
The company's investor-relations page provides its March 2026, June 2026 and audited December 2025 financial statements.
PT Suparma Tbk Financial Statements
PT Suparma Tbk — Official Company Profile
Provides information about the company's manufacturing operations, products, sustainability strategy and recovered-fiber usage.
PT Suparma Tbk Official Company Profile
PT Suparma Tbk — Official Website
Company information, products, investor relations and corporate information.
PT Suparma Tbk Official Website
Reuters — SPMA.JK
Independent market reference for SPMA's business description and market data.
Reuters SPMA.JK Company Page
Indonesia Stock Exchange (IDX)
The Indonesian Stock Exchange is the primary market institution for publicly traded Indonesian companies and should be used to verify official filings and corporate actions.
IPS Research / Indo Premier — 2025 and 2026 Financial Results
Used here as a secondary cross-check for the reported financial figures; the company's own financial statements remain the primary source.
SEO Title
PT Suparma Tbk (SPMA) Stock Analysis 2026: Financials, Valuation, Risks & Outlook
Meta Description
Is PT Suparma Tbk (SPMA) stock undervalued in 2026? Analyze revenue, earnings, ROE, debt, valuation, risks and growth potential for U.S. investors.
Suggested URL Slug
pt-suparma-tbk-spma-stock-analysis-2026
Primary Keyword
PT Suparma Tbk stock
Secondary Keywords
SPMA stock
SPMA stock analysis 2026
PT Suparma Tbk financial analysis
SPMA Indonesia stock
SPMA valuation
SPMA earnings
SPMA stock forecast
Indonesian paper stocks
best Indonesian stocks for foreign investors
SPMA dividend
About the Author
David Mulyana is the founder and editor of WorldReview1989, an independent publication dedicated to finance, investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Personal Finance
- Investing & Stock Market
- Cryptocurrency & Blockchain
- Insurance
- Banking
- Real Estate
- Business & Entrepreneurship
- Digital Marketing
- Financial Technology (FinTech)
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks
Join Facebook Group